Literature DB >> 23355109

Risk factors, pathophysiology, and treatment of hot flashes in cancer.

William I Fisher1, Aimee K Johnson, Gary R Elkins, Julie L Otte, Debra S Burns, Menggang Yu, Janet S Carpenter.   

Abstract

Hot flashes are prevalent and severe symptoms that can interfere with mood, sleep, and quality of life for women and men with cancer. The purpose of this article is to review existing literature on the risk factors, pathophysiology, and treatment of hot flashes in individuals with cancer. Electronic searches were conducted to identify relevant English-language literature published through June 15, 2012. Results indicated that risk factors for hot flashes in cancer include patient-related factors (eg, age, race/ethnicity, educational level, smoking history, cardiovascular risk including body mass index, and genetics) and disease-related factors (eg, cancer diagnosis and dose/type of treatment). In addition, although the pathophysiology of hot flashes has remained elusive, these symptoms are likely attributable to disruptions in thermoregulation and neurochemicals. Therapies that have been offered or tested fall into 4 broad categories: pharmacological, nutraceutical, surgical, and complementary/behavioral strategies. The evidence base for this broad range of therapies varies, with some treatments not yet having been fully tested or showing equivocal results. The evidence base surrounding all therapies is evaluated to enhance hot flash treatment decision-making by clinicians and patients.
Copyright © 2013 American Cancer Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355109      PMCID: PMC3640615          DOI: 10.3322/caac.21171

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  260 in total

1.  Menopausal hot flashes and insulin resistance.

Authors:  Pauliina Tuomikoski; Olavi Ylikorkala; Tomi S Mikkola
Journal:  Menopause       Date:  2012-10       Impact factor: 2.953

2.  Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.

Authors:  Leilani Morales; Patrick Neven; Dirk Timmerman; Marie-Rose Christiaens; Ignace Vergote; Erik Van Limbergen; An Carbonez; Sabine Van Huffel; Lieveke Ameye; Robert Paridaens
Journal:  Anticancer Drugs       Date:  2004-09       Impact factor: 2.248

3.  Endurance exercise effect on quality of life and menopausal symptoms in Nigerian women.

Authors:  O O Ogwumike; A O Sanya; A O Arowojolu
Journal:  Afr J Med Med Sci       Date:  2011-09

4.  Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women.

Authors:  Y A Wyon; A C Spetz; G E Theodorsson; M L Hammar
Journal:  Menopause       Date:  2000 Jan-Feb       Impact factor: 2.953

5.  Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.

Authors:  Piero Sismondi; Rainer Kimmig; Ernst Kubista; Nicoletta Biglia; Jan Egberts; Roel Mulder; Juan Planellas; Giulia Moggio; Mirjam Mol-Arts; Peter Kenemans
Journal:  Maturitas       Date:  2011-10-26       Impact factor: 4.342

6.  Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?

Authors:  N Acs; Z Vajo; C Demendi; G Nádasy; E Monos; B Székács
Journal:  Gynecol Endocrinol       Date:  2001-02       Impact factor: 2.260

7.  Moclobemide in the treatment of hot flashes in postmenopausal women.

Authors:  Ebru Tarim; Tayfun Bagis; Esra Kilicdag; Serkan Erkanli; Erdogan Aslan; Esra Kuscu
Journal:  Adv Ther       Date:  2002 Nov-Dec       Impact factor: 3.845

8.  Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes.

Authors:  R R Freedman
Journal:  Fertil Steril       Date:  1998-08       Impact factor: 7.329

9.  Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.

Authors:  N Biglia; P Sgandurra; E Peano; D Marenco; G Moggio; V Bounous; N Tomasi Cont; R Ponzone; P Sismondi
Journal:  Climacteric       Date:  2009-08       Impact factor: 3.005

10.  Effect of escitalopram on hot flash interference: a randomized, controlled trial.

Authors:  Janet S Carpenter; Katherine A Guthrie; Joseph C Larson; Ellen W Freeman; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Andrea Z LaCroix
Journal:  Fertil Steril       Date:  2012-04-03       Impact factor: 7.490

View more
  12 in total

1.  Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses.

Authors:  Brian Hutton; Mona Hersi; Wei Cheng; Misty Pratt; Pauline Barbeau; Sasha Mazzarello; Nadera Ahmadzai; Becky Skidmore; Scott C Morgan; Louise Bordeleau; Pamela K Ginex; Behnam Sadeghirad; Rebecca L Morgan; Katherine Marie Cole; Mark Clemons
Journal:  Oncol Nurs Forum       Date:  2020-07-01       Impact factor: 2.172

2.  Effects of ultrasound-guided stellate-ganglion block on sleep and regional cerebral oxygen saturation in patients undergoing breast cancer surgery: a randomized, controlled, double-blinded trial.

Authors:  Feng Jin; Xiao-Qian Li; Wen-Fei Tan; Hong Ma; Bo Fang; A-Yong Tian; Huang-Wei Lu
Journal:  J Clin Monit Comput       Date:  2017-10-17       Impact factor: 2.502

3.  Description of an Audio-Based Paced Respiration Intervention for Vasomotor Symptoms.

Authors:  Debra S Burns; Michael R Drews; Janet S Carpenter
Journal:  Music Med       Date:  2013-01-01

4.  MsFLASH participants' priorities for alleviating menopausal symptoms.

Authors:  J S Carpenter; N F Woods; J L Otte; K A Guthrie; C Hohensee; K M Newton; H Joffe; L Cohen; B Sternfeld; R J Lau; S D Reed; A Z LaCroix
Journal:  Climacteric       Date:  2015-10-30       Impact factor: 3.024

5.  A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN).

Authors:  Evgenia Stefanopoulou; Omar Yousaf; Elizabeth A Grunfeld; Myra S Hunter
Journal:  Psychooncology       Date:  2015-03-09       Impact factor: 3.894

6.  CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study.

Authors:  Ishani Wickramage; Kamani Hemamala Tennekoon; Merenchi Arachchige Yasantha Ariyaratne; Asanka Sudeshini Hewage; Tharmini Sundralingam
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-03-06

7.  Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors.

Authors:  Poupak Rahimzadeh; Farnad Imani; Nahid Nafissi; Behzad Ebrahimi; Seyed Hamid Reza Faiz
Journal:  Cancer Manag Res       Date:  2018-10-26       Impact factor: 3.989

Review 8.  Complementary and Alternative Medicine for Menopause.

Authors:  Alisa Johnson; Lynae Roberts; Gary Elkins
Journal:  J Evid Based Integr Med       Date:  2019 Jan-Dec

9.  Stellate ganglion block reduces inflammation and improves neurological function in diabetic rats during ischemic stroke.

Authors:  Ting-Ting Li; Qiang Wan; Xin Zhang; Yuan Xiao; Li-Ying Sun; Yu-Rong Zhang; Xiang-Nan Liu; Wan-Chao Yang
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

10.  Thermoregulation is not impaired in breast cancer survivors during moderate-intensity exercise performed in warm and hot environments.

Authors:  Rebecca L Relf; Ben J Lee; Gregor Eichhorn; Melanie S Flint; Louisa Beale; Neil Maxwell
Journal:  Physiol Rep       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.